These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. What's new in the treatment of advanced prostate cancer? Sternberg CN Eur J Cancer; 2003 Jan; 39(2):136-46. PubMed ID: 12509944 [TBL] [Abstract][Full Text] [Related]
3. Target to apoptosis: a hopeful weapon for prostate cancer. Tang DG; Porter AT Prostate; 1997 Sep; 32(4):284-93. PubMed ID: 9288188 [TBL] [Abstract][Full Text] [Related]
4. Current chemotherapeutic approaches for androgen-independent prostate cancer. Rumohr JA; Chang SS Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023 [TBL] [Abstract][Full Text] [Related]
5. The role of angiogenesis inhibitors in prostate cancer. Aragon-Ching JB; Dahut WL Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479 [TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901 [TBL] [Abstract][Full Text] [Related]
8. The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. Figg WD Clin Pharmacol Ther; 2006 Jan; 79(1):1-8. PubMed ID: 16413236 [No Abstract] [Full Text] [Related]
9. New drugs in prostate cancer. Armstrong AJ; Carducci MA Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849 [TBL] [Abstract][Full Text] [Related]
10. Castration-refractory prostate cancer: New drugs in the pipeline. Schrijvers D; Van Erps P; Cortvriend J Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721 [TBL] [Abstract][Full Text] [Related]
17. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Gulley J; Dahut WL Urology; 2003 Dec; 62 Suppl 1():147-54. PubMed ID: 14747053 [TBL] [Abstract][Full Text] [Related]
18. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372 [TBL] [Abstract][Full Text] [Related]